Genmab A (GMAB) Notes Payables (2025 - 2026)
Genmab A (GMAB) reported Notes Payables of $275.0 million for Q1 2026, up 0.73% quarter-over-quarter from $273.0 million in Q4 2025.
Genmab A (GMAB) Notes Payables (2025 - 2026) Analysis & Trends
Genmab A has reported Notes Payables for 2 years, with the latest figure at $275.0 million in Q1 2026.
- For the quarter ending Q1 2026, Notes Payables changed N/A year-over-year to $275.0 million; the trailing twelve-month figure through Mar 2026 stood at $275.0 million (changed N/A YoY), and the FY2025 full-year result was $273.0 million, changed N/A from the prior year.
- Notes Payables for Q1 2026 stood at $275.0 million, up from $273.0 million in the prior quarter.
- The five-year high for Notes Payables was $275.0 million in Q1 2026, with the low at $273.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Genmab A | 48.34 Bn | 46.82 Bn | 831.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 275.00 Mn |
| Dec 31, 2025 | 273.00 Mn |